Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$0.73 - $2.37 $18,643 - $60,527
25,539 New
25,539 $49,000
Q3 2022

Nov 14, 2022

SELL
$1.53 - $3.39 $18,959 - $42,008
-12,392 Reduced 51.85%
11,510 $18,000
Q2 2022

Aug 15, 2022

BUY
$1.73 - $4.29 $41,350 - $102,539
23,902 New
23,902 $42,000
Q4 2021

Feb 14, 2022

SELL
$2.2 - $4.46 $73,750 - $149,512
-33,523 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$3.85 - $6.44 $45,510 - $76,127
11,821 Added 54.47%
33,523 $131,000
Q2 2021

Aug 16, 2021

SELL
$5.85 - $8.33 $83,227 - $118,510
-14,227 Reduced 39.6%
21,702 $139,000
Q1 2021

May 17, 2021

BUY
$7.8 - $12.43 $280,246 - $446,597
35,929 New
35,929 $291,000

Others Institutions Holding GMDA

# of Institutions
1
Shares Held
2.2K
Call Options Held
0
Put Options Held
0

About Gamida Cell Ltd.


  • Ticker GMDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,319,600
  • Market Cap $2.29M
  • Description
  • Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...
More about GMDA
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.